1. Home
  2. EVT vs HROW Comparison

EVT vs HROW Comparison

Compare EVT & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

EVT

Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

HOLD

Current Price

$28.10

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

HROW

Harrow Inc.

HOLD

Current Price

$32.39

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVT
HROW
Founded
N/A
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2003
2008

Fundamental Metrics

Financial Performance
Metric
EVT
HROW
Price
$28.10
$32.39
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$69.86
AVG Volume (30 Days)
80.7K
450.0K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
71.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$31.62
Revenue Next Year
N/A
$50.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.00
$28.54
52 Week High
$29.65
$54.98

Technical Indicators

Market Signals
Indicator
EVT
HROW
Relative Strength Index (RSI) 39.29 28.24
Support Level $26.98 $28.54
Resistance Level $29.25 $36.37
Average True Range (ATR) 0.38 1.36
MACD -0.15 -0.50
Stochastic Oscillator 26.81 0.28

Price Performance

Historical Comparison
EVT
HROW

About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: